Eisai Buys Global Rights To Cancer Drug Of Japan's Prism BioLab
This article was originally published in PharmAsia News
Executive Summary
Eisai and Prism BioLab, a bioventure, have agreed to jointly develop and market on a global basis Prism's cancer drugs